Just In
- 33 min ago Ramadan 2024: 6 Bollywood-Inspired Outfit Ideas To Shine During The Holy Month
- 2 hrs ago Personality Traits Of April Born Babies: From Being Witty, To Charismatic And More, They Are Full Of Sheer Joy
- 3 hrs ago Festivals In April 2024: Check Out The Full List Of Tyohar And Vrats That Will Fall This Month
- 4 hrs ago April Fool's Day 2024: Strange And Unusual Pranks That Were Pulled Off On 1st April
Don't Miss
- Sports RCB vs KKR My11Circle Prediction IPL 2024 Match 10: BLRvs KOL Fantasy Tips & Expert Picks
- Automobiles Nissan And Renault To Launch Four New SUVs In Strategic Collaboration
- News Arvind Kejriwal Arrest: Sunita Kejriwal Seeks Public Support, Launches ‘Ashirvad’ Campaign For AAP
- Finance SIP Success Stories: These Equity Mutual Funds Turned 10,000 To As Much As 1,64,000 In FY24; Buy?
- Technology BSNL Introduces New Rs 599 and Rs 699 High-Speed Fiber Broadband Plans: Check Details
- Movies 5 Hilarious Roles Of Arshad Warsi That Ticked Our Funny Bone
- Education UGC NET June 2024: Application process to begin next week, Know more
- Travel Explore Tamil Nadu's Diverse Wedding Venues
Antiviral Drugs May Reduce Monkeypox Symptoms, Shorten Contagious Phase: Lancet Study
Some antiviral medications might have the potential to shorten symptoms of monkeypox and reduce the amount of time a patient is contagious, according to a study of seven patients diagnosed with the rare viral disease in the UK between 2018 and 2021.
The cases analysed in the study, published on Tuesday in The Lancet Infectious Diseases journal, represent the first instances of in-hospital transmission and household transmission outside of Africa.
The research also reported the patient's response to the first off-label use of two different antiviral medications - brincidofovir and tecovirimat - to treat the disease.
The study found little evidence that brincidofovir was of clinical benefit but concluded that further research into the potential of tecovirimat would be warranted.
The researchers also report the detection of the monkeypox virus in blood and throat swabs. As optimum infection control and treatment strategies for this disease are not yet established, data from the study could help inform global efforts to further understand the clinical features of the disease as well as transmission dynamics, they said.
"As public health officials are trying to understand what is causing the May 2022 monkeypox outbreaks in Europe and North America-which have affected several patients who reported neither travel nor an identified link to a previously known case-our study offers some of the first insights into the use of antivirals for the treatment of monkeypox in humans," said Hugh Adler of the Liverpool University Hospitals NHS Foundation Trust, UK.
Also
Read
|Expert:
Monkeypox
likely
spread
by
sex
at
2
raves
in
Europe
"Although
this
latest
outbreak
has
affected
more
patients
than
we
had
previously
encountered
in
the
UK,
historically
monkeypox
has
not
transmitted
very
efficiently
between
people,
and
overall
the
risk
to
public
health
is
low,"
Adler,
lead
author
of
the
paper,
said.
With international travel returning to pre-pandemic levels, public health officials and healthcare workers around the world must remain vigilant to the possibility of new cases of monkeypox, said Nick Price of Guy's & St. Thomas' NHS Foundation Trust, senior author of the paper.
Of the seven UK monkeypox cases analysed in the study, four were imported from West Africa, with three further cases occurring due to human-to-human transmission within the case clusters.
Monkeypox, a close relative of the smallpox virus, is a rare disease classified as a High Consequence Infectious Disease (HCID) by the UK Health Security Agency.
There are currently no licensed treatments for monkeypox and there is limited data on the duration of its contagiousness, with the incubation period ranging from five to 21 days.
The study authors observed clinical data alongside laboratory results from blood tests and nose-and-throat swabs to describe the duration and clinical features of monkeypox in a high-income setting. Researchers also reported patient response to antiviral medications developed to treat smallpox-brincidofovir and tecovirimat-which have previously demonstrated some efficacy against monkeypox in animals.
Between 2018 and 2019, four patients observed in the study were treated for monkeypox in HCID units in England. Three of these cases were imported from West Africa.
The fourth case occurred in a healthcare worker 18 days after initial exposure to the virus and was the first example of monkeypox transmission in a hospital setting outside of Africa.
The initial three patients were treated with brincidofovir seven days after the initial onset of the rash.
Must
Read
|Monkeypox:
Health
officials
at
airports,
borders
asked
to
keep
a
close
watch
on
symptomatic
travellers
from
Africa
The
study
found
that
brincidofovir
did
not
have
any
convincing
clinical
benefit
in
treating
monkeypox
and
alterations
in
liver
blood
tests
were
observed.
The researchers noted that it is not known whether brincidofovir administration earlier in the course of the disease or at a different dosing schedule would have yielded different clinical outcomes.
Despite this, all three patients, plus the fourth hospital transmission patient, made a full recovery, they said.
Three further cases of monkeypox were reported in the UK in 2021 in a family travelling from Nigeria, with two of these cases being the first examples of household transmission outside of Africa.
One of the 2021 UK patients was treated with tecovirimat and experienced a shorter duration of symptoms and upper respiratory tract viral shedding than the other cases in this cluster, the researchers said.
However, they note that conclusions are unable to be drawn on antiviral effectiveness against monkeypox in such a small cohort, calling for further research into antivirals to treat this neglected tropical disease.
"During previous outbreaks of monkeypox, patients were considered infectious until all lesions crusted over," said Catherine Houlihan, of the UK Health Security Agency and University College London, one of the co-authors of the paper.
"In these seven UK cases, viral shedding was observed for at least three weeks following infection. However, data on infectivity remains limited, and is an important area for future study," said Houlihan.
The authors acknowledge some limitations with this study, primarily its observational nature and the small number of cases analysed.
They were also unable to confirm positive monkeypox PCR test results with laboratory samples of the virus, meaning that ongoing shedding of contagious virus was unable to be verified.
- kidsTwin Viral Concerns Of COVID-19 And Monkeypox In Kids: What Parents Should Know
- wellnessCommon Household Items Can Carry Monkeypox, CDC: What You Should Know
- wellnessPets Should Be Isolated From Monkeypox Patients: WHO
- wellnessCan Washing Clothes Eliminate Monkeypox? Steps To Get Rid Of The Monkeypox Virus Through Laundry
- disorders cureAsymptomatic Monkeypox: Its Health Complications, Vaccine And Dos & Don'ts
- disorders cureMonkeypox vs Chickenpox: Know The Difference; If You Had Chickenpox, Are You Safe?
- wellnessIndia Reports Second Confirmed Case Of Monkeypox From Kerala's Kannur: Official
- wellnessMonkeypox: Kerala Steps Up Vigil, Issues Special Alerts To Five Districts
- wellnessCovid-19 Vaccines Don't Cause Monkeypox, Shingles
- wellnessGovt Releases Monkeypox Guidelines On Detecting And Treating The Disease
- wellnessMonkeypox: We Have Vaccines And Drugs To Treat It
- wellnessCentre Advises Isolation Of Suspected Monkeypox Cases At Designated Health Facilities